Revolution Medicines (RVMD) Competitors $44.06 +0.77 (+1.78%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RVMD vs. BNTX, TEVA, BGNE, MRNA, VTRS, SMMT, GMAB, RDY, SRPT, and CTLTShould you be buying Revolution Medicines stock or one of its competitors? The main competitors of Revolution Medicines include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Moderna (MRNA), Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), and Catalent (CTLT). These companies are all part of the "pharmaceutical products" industry. Revolution Medicines vs. BioNTech Teva Pharmaceutical Industries BeiGene Moderna Viatris Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Sarepta Therapeutics Catalent Revolution Medicines (NASDAQ:RVMD) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations, community ranking and risk. Is RVMD or BNTX more profitable? Revolution Medicines has a net margin of 0.00% compared to BioNTech's net margin of -15.16%. BioNTech's return on equity of -2.35% beat Revolution Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Revolution MedicinesN/A -33.67% -30.08% BioNTech -15.16%-2.35%-2.05% Do institutionals & insiders hold more shares of RVMD or BNTX? 94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 8.0% of Revolution Medicines shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate RVMD or BNTX? Revolution Medicines presently has a consensus price target of $65.82, suggesting a potential upside of 49.38%. BioNTech has a consensus price target of $140.76, suggesting a potential upside of 24.48%. Given Revolution Medicines' stronger consensus rating and higher possible upside, analysts plainly believe Revolution Medicines is more favorable than BioNTech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revolution Medicines 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09BioNTech 0 Sell rating(s) 4 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.82 Does the MarketBeat Community favor RVMD or BNTX? BioNTech received 49 more outperform votes than Revolution Medicines when rated by MarketBeat users. However, 75.63% of users gave Revolution Medicines an outperform vote while only 45.87% of users gave BioNTech an outperform vote. CompanyUnderperformOutperformRevolution MedicinesOutperform Votes9075.63% Underperform Votes2924.37% BioNTechOutperform Votes13945.87% Underperform Votes16454.13% Which has preferable earnings & valuation, RVMD or BNTX? BioNTech has higher revenue and earnings than Revolution Medicines. BioNTech is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevolution Medicines$742K9,988.85-$436.37M-$3.59-12.27BioNTech$3.04B8.84$1.01B-$2.10-53.85 Does the media prefer RVMD or BNTX? In the previous week, Revolution Medicines had 5 more articles in the media than BioNTech. MarketBeat recorded 12 mentions for Revolution Medicines and 7 mentions for BioNTech. BioNTech's average media sentiment score of 0.66 beat Revolution Medicines' score of 0.62 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, RVMD or BNTX? Revolution Medicines has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500. SummaryRevolution Medicines and BioNTech tied by winning 9 of the 18 factors compared between the two stocks. Ad DTICackling Kamala hates this companyDo you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution. Before that happens, you need to see the details here. Get Revolution Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RVMD vs. The Competition Export to ExcelMetricRevolution MedicinesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.28B$2.94B$5.13B$9.08BDividend YieldN/A1.90%4.93%4.22%P/E Ratio-12.2746.7389.6617.18Price / Sales9,988.85415.011,115.28116.98Price / CashN/A182.1042.8237.86Price / Book3.973.894.794.78Net Income-$436.37M-$42.21M$120.04M$225.60M7 Day Performance-2.11%-2.15%-1.91%-1.23%1 Month Performance-22.40%4.20%11.48%3.36%1 Year Performance67.72%18.39%30.60%16.60% Revolution Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVMDRevolution Medicines4.5486 of 5 stars$44.06+1.8%$65.82+49.4%+71.5%$7.28B$742,000.00-12.27443Insider TradeBNTXBioNTech2.0896 of 5 stars$114.07-5.2%$140.76+23.4%+10.0%$27.12B$3.04B-56.016,133TEVATeva Pharmaceutical Industries1.8881 of 5 stars$16.65+0.9%$19.67+18.1%+112.2%$18.86B$16.77B-19.7937,851Analyst DowngradeOptions VolumeNews CoverageBGNEBeiGene2.6145 of 5 stars$176.80-1.4%$253.69+43.5%+0.7%$17.23B$2.46B-21.7710,600MRNAModerna4.2706 of 5 stars$41.65-0.4%$79.50+90.9%-54.3%$16.03B$5.06B-7.195,600Analyst DowngradeVTRSViatris2.056 of 5 stars$12.69+0.5%$13.67+7.7%+19.8%$15.15B$15.05B-17.0738,000News CoverageSMMTSummit Therapeutics3.2703 of 5 stars$18.81+5.5%$33.33+77.2%+636.9%$13.87B$700,000.00-63.68105News CoverageGap DownGMABGenmab A/S4.2345 of 5 stars$20.14-0.1%$45.20+124.4%-33.5%$13.33B$19.84B19.582,204Positive NewsHigh Trading VolumeRDYDr. Reddy's Laboratories1.86 of 5 stars$14.76+2.1%$17.00+15.2%+15.8%$12.32B$299.87B22.9527,048Analyst DowngradeNews CoverageGap UpSRPTSarepta Therapeutics4.8145 of 5 stars$126.12+1.9%$178.71+41.7%+31.8%$12.05B$1.64B98.971,314Analyst ForecastCTLTCatalent2.7663 of 5 stars$63.48+0.7%$63.40-0.1%N/A$11.52B$4.38B-27.9116,900High Trading Volume Related Companies and Tools Related Companies BNTX Alternatives TEVA Alternatives BGNE Alternatives MRNA Alternatives VTRS Alternatives SMMT Alternatives GMAB Alternatives RDY Alternatives SRPT Alternatives CTLT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RVMD) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revolution Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
